These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

945 related items for PubMed ID: 28735292

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Ranolazine Prevents Phenotype Development in a Mouse Model of Hypertrophic Cardiomyopathy.
    Coppini R, Mazzoni L, Ferrantini C, Gentile F, Pioner JM, Laurino A, Santini L, Bargelli V, Rotellini M, Bartolucci G, Crocini C, Sacconi L, Tesi C, Belardinelli L, Tardiff J, Mugelli A, Olivotto I, Cerbai E, Poggesi C.
    Circ Heart Fail; 2017 Mar; 10(3):. PubMed ID: 28255011
    [Abstract] [Full Text] [Related]

  • 3. Novel insights on the relationship between T-tubular defects and contractile dysfunction in a mouse model of hypertrophic cardiomyopathy.
    Crocini C, Ferrantini C, Scardigli M, Coppini R, Mazzoni L, Lazzeri E, Pioner JM, Scellini B, Guo A, Song LS, Yan P, Loew LM, Tardiff J, Tesi C, Vanzi F, Cerbai E, Pavone FS, Sacconi L, Poggesi C.
    J Mol Cell Cardiol; 2016 Feb; 91():42-51. PubMed ID: 26714042
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Dilated cardiomyopathy mutations in thin-filament regulatory proteins reduce contractility, suppress systolic Ca2+, and activate NFAT and Akt signaling.
    Robinson P, Sparrow AJ, Patel S, Malinowska M, Reilly SN, Zhang YH, Casadei B, Watkins H, Redwood C.
    Am J Physiol Heart Circ Physiol; 2020 Aug 01; 319(2):H306-H319. PubMed ID: 32618513
    [Abstract] [Full Text] [Related]

  • 6. In Vivo Analysis of Troponin C Knock-In (A8V) Mice: Evidence that TNNC1 Is a Hypertrophic Cardiomyopathy Susceptibility Gene.
    Martins AS, Parvatiyar MS, Feng HZ, Bos JM, Gonzalez-Martinez D, Vukmirovic M, Turna RS, Sanchez-Gonzalez MA, Badger CD, Zorio DAR, Singh RK, Wang Y, Jin JP, Ackerman MJ, Pinto JR.
    Circ Cardiovasc Genet; 2015 Oct 01; 8(5):653-664. PubMed ID: 26304555
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Hypertrophic cardiomyopathy-linked mutation in troponin T causes myofibrillar disarray and pro-arrhythmic action potential changes in human iPSC cardiomyocytes.
    Wang L, Kim K, Parikh S, Cadar AG, Bersell KR, He H, Pinto JR, Kryshtal DO, Knollmann BC.
    J Mol Cell Cardiol; 2018 Jan 01; 114():320-327. PubMed ID: 29217433
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Hypertrophic cardiomyopathy mutation in cardiac troponin T (R95H) attenuates length-dependent activation in guinea pig cardiac muscle fibers.
    Mickelson AV, Chandra M.
    Am J Physiol Heart Circ Physiol; 2017 Dec 01; 313(6):H1180-H1189. PubMed ID: 28842439
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Chronic Calmodulin-Kinase II Activation Drives Disease Progression in Mutation-Specific Hypertrophic Cardiomyopathy.
    Lehman SJ, Tal-Grinspan L, Lynn ML, Strom J, Benitez GE, Anderson ME, Tardiff JC.
    Circulation; 2019 Mar 19; 139(12):1517-1529. PubMed ID: 30586744
    [Abstract] [Full Text] [Related]

  • 17. Perturbed length-dependent activation in human hypertrophic cardiomyopathy with missense sarcomeric gene mutations.
    Sequeira V, Wijnker PJ, Nijenkamp LL, Kuster DW, Najafi A, Witjas-Paalberends ER, Regan JA, Boontje N, Ten Cate FJ, Germans T, Carrier L, Sadayappan S, van Slegtenhorst MA, Zaremba R, Foster DB, Murphy AM, Poggesi C, Dos Remedios C, Stienen GJ, Ho CY, Michels M, van der Velden J.
    Circ Res; 2013 May 24; 112(11):1491-505. PubMed ID: 23508784
    [Abstract] [Full Text] [Related]

  • 18. Desensitization of myofilaments to Ca2+ as a therapeutic target for hypertrophic cardiomyopathy with mutations in thin filament proteins.
    Alves ML, Dias FAL, Gaffin RD, Simon JN, Montminy EM, Biesiadecki BJ, Hinken AC, Warren CM, Utter MS, Davis RT, Sakthivel S, Robbins J, Wieczorek DF, Solaro RJ, Wolska BM.
    Circ Cardiovasc Genet; 2014 Apr 24; 7(2):132-143. PubMed ID: 24585742
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Mutation location of HCM-causing troponin T mutations defines the degree of myofilament dysfunction in human cardiomyocytes.
    Schuldt M, Johnston JR, He H, Huurman R, Pei J, Harakalova M, Poggesi C, Michels M, Kuster DWD, Pinto JR, van der Velden J.
    J Mol Cell Cardiol; 2021 Jan 24; 150():77-90. PubMed ID: 33148509
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.